Singapore markets closed

Alnylam Pharmaceuticals, Inc. (0HD2.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
149.05-0.26 (-0.17%)
As of 05:51PM BST. Market open.

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142
United States
617 551 8200

Full-time employees2,100

Key executives

NameTitlePayExercisedYear born
Dr. Yvonne L. Greenstreet M.B.A., MBChBCEO & Director2.15MN/A1963
Mr. Jeffrey V. Poulton M.B.A.CFO & Executive VP1.05MN/A1968
Dr. Akshay K. Vaishnaw M.D., Ph.D.Chief Innovation Officer & Member of the Scientific Advisory Board1.12M5.9M1963
Dr. Pushkal P. Garg M.D.Chief Medical Officer and Executive VP of Development & Medical Affairs1.06M517.75k1968
Mr. Tolga Tanguler M.B.A.Executive VP & Chief Commercial Officer971.3kN/A1973
Mr. Timothy J. MainesChief Technical Operations & Quality OfficerN/AN/AN/A
Dr. Kevin Joseph Fitzgerald Ph.D.Senior VP, Head of Research & Chief Scientific OfficerN/AN/A1969
Ms. Christine Regan LindenboomSenior VP of Investor Relations & Corporate CommunicationsN/AN/A1981
Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerN/AN/AN/A
Mr. Evan Lippman M.B.A.Chief Corporate Development & Strategy OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Alnylam Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2024 is 4. The pillar scores are Audit: 6; Board: 2; Shareholder rights: 6; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.